Skip to main content
Evidence Snapshot

Protein-tyrosine kinase 6

CHEMBL4601 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4601
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein-tyrosine kinase 6 as ChEMBL target CHEMBL4601, mapped to UniProt Q13882. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein-tyrosine kinase 6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4601
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13882
Protein-tyrosine kinase 6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Protein-tyrosine kinase 6 matters

As of 2026-09-13

Protein-tyrosine kinase 6 is reviewed as Protein-tyrosine kinase 6 (UniProt Q13882); Protein-tyrosine kinase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 19 approved drugs, 1877 compounds, and 324 assays, with lead potency reaching pChEMBL 8.7.

Disease context
cancer

Protein-tyrosine kinase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include VANDETANIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include VANDETANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 19 approved drugs, 1877 compounds, and 324 assays for this target. The dominant activity type is KI. CHEMBL1836842 is the current potency anchor at pChEMBL 8.7.

Use CHEMBL1836842 as the tractability anchor when discussing potency (pChEMBL 8.7).

Activity source · ChEMBL 36 via Core Engine
19 approved pChEMBL 8.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Protein-tyrosine kinase 6 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13882, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1877
Total Compounds
324
Total Assays
19
Approved Drugs
IC50: 397.0, KI: 403.0, KD: 385.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1836842
 8.7 IC50 —
No preferred name
CHEMBL5800577
 8.7 IC50 —
No preferred name
CHEMBL5874804
 8.7 IC50 —
No preferred name
CHEMBL450519
 8.7 Kd —
No preferred name
CHEMBL249097
 8.7 Kd —

Approved Drugs

Structure Compound First Approval
ZANUBRUTINIB
CHEMBL3936761
 2019
ENTRECTINIB
CHEMBL1983268
 2019
BRIGATINIB
CHEMBL3545311
 2017
TIVOZANIB
CHEMBL1289494
 2017
LENVATINIB
CHEMBL1289601
 2015
IBRUTINIB
CHEMBL1873475
 2013
VANDETANIB
CHEMBL24828
 2011
DASATINIB
CHEMBL5416410
 2006
DASATINIB ANHYDROUS
CHEMBL1421
 2006
GEFITINIB
CHEMBL939
 2003
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4601